In like a lion, out like a lion: The Tipline for 12 October 2021
Rohit Chopra has left the Federal Trade Commission, but not before taking one final shot at the agency’s antitrust record. In his final statement as commissioner, the progressive firebrand said the merger remedies study published by the commission in 2017 greatly exaggerated the effectiveness of divestitures the FTC required for several pharmaceutical deals. “I believe the study should not be cited by the public going forward,” Chopra said, without specifying what he viewed as the study’s deficiencies.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10